– Late-breaking Phase III results show subcutaneous injection was non-inferior to intravenous infusion based on Ocrevus levels in the blood over 12 weeks – – Ocrevus subcutaneous injection was ...
You are able to gift 5 more articles this month. Anyone can access the link you share with no account required. Learn more. DEAR DR. ROACH: I have had osteoporosis for a while and recently had a bone ...
B. Braun Medical Inc. (B. Braun), a recognized leader in infusion therapy and pharmaceutical manufacturing, announced the launch of Midazolam in 0.8% Sodium Chloride Injection in the U.S. market. The ...
Azurity Pharmaceuticals, Inc. announced today that the U.S. Food and Drug Administration (FDA) has approved FerabrightTM ...
Roche Holdings AG's RHHBY Phase 3 OCARINA II trial evaluating Ocrevus (ocrelizumab) as a twice-a-year 10-minute subcutaneous injection met its primary and secondary endpoints in patients with ...
Self-administration of rozanolixizumab, a neonatal Fc receptor blocker (FcRn) indicated for generalized myasthenia gravis, ...
Pharmaceutical infusion center operator Infusion Express has received a $22.5 million round of growth funding and rebranded as IVX Health. The Brentwood-based company raised the capital to continue ...
DEAR DR. ROACH: I have had osteoporosis for a while and recently had a bone density test that again confirmed that I have it. I am not really interested in taking an oral prescription such as Fosamax, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback